Oral Minoxidil in Androgenic Alopecia: Retrospective Study on Its Safety in Real Clinical Practice

    May 2021 in “ e_Buah ”
    Macarena de los Ríos Zosino
    Studysummary In this descriptive retrospective study, researchers reported that low-dose oral minoxidil (0.25-5mg/day) for androgenic alopecia demonstrated a good safety profile, with 84.4% of 641 patients experiencing no adverse effects and only 1.4% discontinuing due to side effects that resolved with dose reduction or withdrawal.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on ebuah.uah.es →
    Discuss this study in the Community →